| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| b' G M Prelevi\\xc4\\x87, M I Wurzburger, L Balint-Peri\\xc4\\x87, J S Nesi\\xc4\\x8. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet (London, England). vol 336. issue 8720. 1990-11-13. PMID:1976930.' |
somatostatin inhibits insulin and lh secretion in healthy adults, so the effect of treatment with a long-acting somatostatin analogue ('sandostatin') on gonadotropin and androgen secretion in pcos was investigated. |
1990-11-13 |
2023-08-11 |
Not clear |
| J J Holst, C G Ostenson, H Harling, T Messel. Porcine pancreastatin has no effect on endocrine secretion from the pig pancreas. Diabetologia. vol 33. issue 7. 1990-10-26. PMID:1976102. |
pancreastatin in a concentration of 10(-8) mol/l had no effect on basal secretion of insulin, glucagon and somatostatin at a perfusate glucose concentration of 5 mmol/l (n = 4) and neither at 10(-8) nor 10(-7) mol/l influenced the hormone responses to acute elevations of perfusate glucose concentration from 3.5 to 11 mmol/l (n = 7). |
1990-10-26 |
2023-08-11 |
Not clear |
| S E Kahn, L J Klaff, M W Schwartz, J C Beard, R N Bergman, G J Taborsky, D Port. Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. The Journal of clinical endocrinology and metabolism. vol 71. issue 4. 1990-10-23. PMID:2205630. |
to determine the specific alteration in b-cell function caused by a somatostatin analog in man and to determine the effect of the induced insulin deficiency on insulin action, we administered octreotide (sms 201-995; 50 micrograms twice daily) to nine healthy male subjects, aged 24-35 yr. b-cell function was assessed by measuring the acute insulin response (air) to glucose (airglucose) at fasting glucose and to arginine (airarg) at glucose concentrations of fasting, approximately 14 and more than 28 mm after 2 (n = 7) and 8 days (n = 9) of octreotide. |
1990-10-23 |
2023-08-11 |
human |
| R H Goodman, R P Rehfuss, M Verhave, R Ventimiglia, M J Lo. Somatostatin gene regulation: an overview. Metabolism: clinical and experimental. vol 39. issue 9 Suppl 2. 1990-10-19. PMID:1976213. |
originally characterized as a hypothalamic regulator of growth hormone secretion, somatostatin also regulates the secretion of several other pituitary, pancreatic, and gastrointestinal (gi) hormones including thyrotropin-stimulating hormone, insulin, glucagon, and gastrin. |
1990-10-19 |
2023-08-11 |
Not clear |
| J E Geric. Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. Metabolism: clinical and experimental. vol 39. issue 9 Suppl 2. 1990-10-19. PMID:1976221. |
somatostatin secreted by pancreatic d cells is a potent inhibitor of insulin, glucagon and growth hormone secretion, as well as other cells. |
1990-10-19 |
2023-08-11 |
Not clear |
| E Samols, J I Stagne. Islet somatostatin--microvascular, paracrine, and pulsatile regulation. Metabolism: clinical and experimental. vol 39. issue 9 Suppl 2. 1990-10-19. PMID:1976222. |
we have shown by the anterograde and retrograde infusion of antibody directed against insulin, glucagon, or somatostatin into the isolated rat and dog pancreas that blood flow within the islet is from the b-cell core outward to the mantle. |
1990-10-19 |
2023-08-11 |
rat |
| E Samols, J I Stagne. Islet somatostatin--microvascular, paracrine, and pulsatile regulation. Metabolism: clinical and experimental. vol 39. issue 9 Suppl 2. 1990-10-19. PMID:1976222. |
our results demonstrate that the b to a to d cellular order of perfusion is responsible for the regulation of islet hormone secretion, ie, insulin regulates the secretion of glucagon and glucagon (and probably insulin) regulate the secretion of somatostatin. |
1990-10-19 |
2023-08-11 |
rat |
| E Samols, J I Stagne. Islet somatostatin--microvascular, paracrine, and pulsatile regulation. Metabolism: clinical and experimental. vol 39. issue 9 Suppl 2. 1990-10-19. PMID:1976222. |
although each hormone is secreted as pulses, there does not appear to be a consistent phase relationship between insulin, glucagon, or somatostatin. |
1990-10-19 |
2023-08-11 |
rat |
| V L Hood, U Keller, M W Haymond, D Kür. Systemic pH modifies ketone body production rates and lipolysis in humans. The American journal of physiology. vol 259. issue 3 Pt 1. 1990-10-18. PMID:1975988. |
somatostatin, with insulin, glucagon, and growth hormone replacement, was infused in all studies. |
1990-10-18 |
2023-08-11 |
human |
| G Bertrand, R Gross, G Ribes, M M Loubatières-Marian. P2 purinoceptor agonists stimulate somatostatin secretion from dog pancreas. European journal of pharmacology. vol 182. issue 2. 1990-10-17. PMID:1975783. |
this atp analogue (approximately 15 microm) immediately induced stimulation of both somatostatin and insulin secretion, which was accompanied by a slight reduction of glycemia. |
1990-10-17 |
2023-08-11 |
dog |
| G Bertrand, R Gross, G Ribes, M M Loubatières-Marian. P2 purinoceptor agonists stimulate somatostatin secretion from dog pancreas. European journal of pharmacology. vol 182. issue 2. 1990-10-17. PMID:1975783. |
under these conditions, alpha,beta-methylene adp immediately induced the stimulation of somatostatin secretion without affecting basal insulin and glucagon secretion. |
1990-10-17 |
2023-08-11 |
dog |
| S Ullrich, M Prentki, C B Wollhei. Somatostatin inhibition of Ca2(+)-induced insulin secretion in permeabilized HIT-T15 cells. The Biochemical journal. vol 270. issue 1. 1990-10-11. PMID:1975739. |
somatostatin inhibition of ca2(+)-induced insulin secretion in permeabilized hit-t15 cells. |
1990-10-11 |
2023-08-11 |
Not clear |
| S Ullrich, M Prentki, C B Wollhei. Somatostatin inhibition of Ca2(+)-induced insulin secretion in permeabilized HIT-T15 cells. The Biochemical journal. vol 270. issue 1. 1990-10-11. PMID:1975739. |
somatostatin inhibited ca2(+)-induced insulin secretion in permeabilized hit-t15 cells, albeit with decreased sensitivity relative to intact cells. |
1990-10-11 |
2023-08-11 |
Not clear |
| C Chambrier, S Picard, H Vidal, R Cohen, J P Riou, M Beylo. Interactions of glucagon and free fatty acids with insulin in control of glucose metabolism. Metabolism: clinical and experimental. vol 39. issue 9. 1990-10-04. PMID:1975421. |
to study the interactions of physiological glucagon and free fatty acids (ffa) concentrations with insulin in the control of glucose metabolism, we determined in normal subjects the response of endogenous glucose production (egp) and glucose utilization (rd) to a progressive and moderate increase of insulinemia in the presence of glucagon and ffa levels either decreased (somatostatin [srif] and insulin infusion, c test) or maintained to normal postabsorptive values isolated (srif + insulin + glucagon infusion, g test; srif + insulin + intralipid infusion, il test) or in association (srif + insulin + glucagon + intralipid infusion, il + g test). |
1990-10-04 |
2023-08-11 |
human |
| N Lertprasertsuke, K Kakudo, S Satoh, N Tada, Y Osamur. Rectal carcinoid tumor metastasizing to the thyroid and pancreas. An autopsy case exploiting immunohistochemistry for differentiation from tumors involving multiple endocrine organs. Acta pathologica japonica. vol 40. issue 5. 1990-10-04. PMID:1975468. |
the neoplastic cells in all involved organs commonly expressed positive immunoreactivity for somatostatin, but negativity for carcinoembryonic antigen, calcitonin, calcitonin gene-related peptide, thyroglobulin, insulin, glucagon and pancreatic polypeptide. |
1990-10-04 |
2023-08-11 |
Not clear |
| M Walker, G R Fulcher, C Catalano, G Petranyi, H Orskov, K G Albert. Physiological levels of plasma non-esterified fatty acids impair forearm glucose uptake in normal man. Clinical science (London, England : 1979). vol 79. issue 2. 1990-10-03. PMID:2167806. |
insulin, glucagon and somatostatin were administered from 60 to 210 min in each study and euglycaemia was maintained. |
1990-10-03 |
2023-08-11 |
human |
| S W Lamberts, E P Krenning, J G Klijn, J C Reub. The clinical use of somatostatin analogues in the treatment of cancer. Bailliere's clinical endocrinology and metabolism. vol 4. issue 1. 1990-09-24. PMID:1975166. |
sandostatin is an analogue of somatostatin which has characteristics which makes it a better compound for clinical use than native somatostatin: it inhibits gh preferentially over insulin. |
1990-09-24 |
2023-08-11 |
human |
| M Krempf, S Ranganathan, J P Remy, B Charbonnel, J Guillo. Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. International journal of clinical pharmacology, therapy, and toxicology. vol 28. issue 7. 1990-09-21. PMID:2387655. |
effect of long-acting somatostatin analog (sms 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. |
1990-09-21 |
2023-08-11 |
human |
| P J Pacy, K N Cheng, G C Ford, D Hallida. Influence of glucagon on protein and leucine metabolism: a study in fasting man with induced insulin resistance. The British journal of surgery. vol 77. issue 7. 1990-09-20. PMID:1974474. |
in one study somatostatin alone was infused continuously (0.12 mg h-1) and in another with glucagon (0.04 mg h-1) to generate insulin resistance. |
1990-09-20 |
2023-08-11 |
human |
| T Kawagish. [The effect of growth hormone-releasing factor (GRF) on secretion of insulin, glucagon and somatostatin from perfused rat pancreas]. Nihon Naibunpi Gakkai zasshi. vol 66. issue 5. 1990-09-17. PMID:1974524. |
[the effect of growth hormone-releasing factor (grf) on secretion of insulin, glucagon and somatostatin from perfused rat pancreas]. |
1990-09-17 |
2023-08-11 |
rat |